SPRY ARS Pharmaceuticals, Inc.

NASDAQ
$2.79

ARS Pharmaceuticals, Inc. (SPRY) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.35 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.9% since its last earnings release on November 5, 2026.

ARS Pharmaceuticals, Inc. Missed Consensus Estimates
Thursday, November 5, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.35)
Rev est $27.54M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.79

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.